Gynecologic oncology is a surgical subspecialty focused on cancers of the female reproductive system. It covers six cancer types: cervical, ovarian, uterine, vaginal, vulvar, and the rare fallopian tube cancer. Gynecologic oncologists are trained to diagnose, surgically treat, and manage these cancers from first detection through long-term follow-up, combining the skills of a surgeon, a cancer specialist, and an OB/GYN into one provider.
The Cancers It Covers
Gynecologic cancers begin when cells in a reproductive organ grow out of control. Each type is named for the organ where it starts:
- Uterine cancer begins in the uterus and is the most common gynecologic cancer. Its incidence and death rates are currently rising, bucking the downward trend seen in most other cancers.
- Ovarian cancer starts in the ovaries, though some cases actually originate in the fallopian tubes or the tissue lining the abdomen (the peritoneum). Incidence and mortality rates have been declining in recent years.
- Cervical cancer begins in the lower, narrow end of the uterus. New cases are declining overall, but the proportion diagnosed at a late stage jumped from around 52% in 2017 to nearly 58% by 2021, meaning more people are being caught with advanced disease.
- Vaginal cancer starts in the canal between the uterus and the outside of the body.
- Vulvar cancer begins in the external genital tissue.
Each of these cancers behaves differently, responds to different treatments, and requires its own surgical approach. That range is a big part of why gynecologic oncology exists as a distinct specialty.
How a Gynecologic Oncologist Is Trained
Becoming a gynecologic oncologist takes well over a decade of training. After medical school, a physician completes a four-year residency in obstetrics and gynecology. From there, they enter a fellowship program specifically in gynecologic oncology, requiring at least 36 months of additional training. During that fellowship, they learn complex cancer surgeries, chemotherapy management, and how to coordinate care with radiation oncologists and other specialists. They then sit for a subspecialty certification exam through the American Board of Obstetrics and Gynecology.
Why Specialist Care Matters
One of the clearest arguments for gynecologic oncology as a specialty comes from survival data. A large study published in the Journal of Clinical Oncology looked at women with endometrial (uterine) cancer and compared outcomes based on whether a gynecologic oncologist managed their care. For women with advanced-stage disease, five-year survival was 72% with a gynecologic oncologist compared to 64% without one. For aggressive tumor types, survival was 81% versus 75%. On multivariate analysis, having a gynecologic oncologist was an independent factor in better survival, separate from age, stage, or tumor grade.
These differences aren’t small. They likely stem from the specialist’s ability to perform more thorough surgical staging, select appropriate follow-up treatments, and recognize when aggressive intervention will help versus when it won’t.
What Treatment Looks Like
Surgery is central to gynecologic oncology. The specific operation depends on the cancer type and how far it has spread. For cancers confined to the uterus or ovaries, a hysterectomy (removing the uterus and sometimes the ovaries, fallopian tubes, and cervix) is often the primary treatment. For ovarian cancer that has spread into the abdomen or pelvis, a more extensive procedure called debulking surgery aims to remove as much visible tumor as possible. Surgeons achieve “optimal debulking,” where all visible cancer or only tiny fragments remain, about 47% of the time. That rate climbs to 77% when chemotherapy or radiation is given before surgery to shrink tumors first.
During debulking, the surgeon may also place heated chemotherapy directly into the abdominal cavity, delivering treatment right where cancer cells are most concentrated. This approach reflects how gynecologic oncologists blend surgical and medical cancer treatment in a single procedure.
Newer Drug Therapies
Beyond surgery and traditional chemotherapy, gynecologic oncologists now use two major categories of newer drugs. The first are drugs that block a DNA repair pathway cancer cells rely on to survive. These work best in ovarian cancers with specific genetic mutations, particularly BRCA mutations, and have shown significant improvements in how long patients stay cancer-free. The second category is immunotherapy, which helps the immune system recognize and attack cancer cells. Immunotherapy has become a frontline treatment for advanced endometrial cancer and is increasingly used in cervical cancer, particularly when tumors have certain molecular markers that predict a strong response.
These treatments are matched to each patient’s tumor biology through genetic and molecular testing, which is another core part of what gynecologic oncologists coordinate.
Symptoms That Lead to a Referral
Abnormal vaginal bleeding or discharge is the most common warning sign shared across nearly all gynecologic cancers (except vulvar cancer). Any vaginal bleeding after menopause warrants prompt medical attention. Before menopause, periods that are heavier than usual, last longer than normal, or bleeding between periods should be evaluated.
Ovarian cancer has a different set of signals: feeling full quickly, bloating, and persistent abdominal or back pain. Pelvic pain or pressure is common in both ovarian and uterine cancers. Frequent or urgent urination and constipation can point to ovarian or vaginal cancer. Vulvar cancer stands apart with its own symptoms: itching, burning, pain, or visible skin changes like sores, rashes, or color changes on the vulva.
Any of these symptoms lasting two weeks or longer and not explained by something else is worth discussing with a doctor.
When Patients Get Referred to This Specialist
The Society of Gynecologic Oncology has published referral guidelines specifying when a patient should see a gynecologic oncologist rather than a general OB/GYN or surgeon. In practice, the threshold is fairly low for anything suspicious. All women with a suspected ovarian malignancy should be offered a consultation before surgery. For uterine cancer, referral helps determine the right surgical approach and whether additional treatment is needed afterward. A visible growth on the cervix or a biopsy confirming invasive cervical cancer triggers referral.
Pelvic masses also warrant specialist involvement when they look concerning: large (over 10 cm), complex, fixed in place, present on both sides, or accompanied by elevated tumor markers or fluid buildup in the abdomen. For vaginal and vulvar cancers, referral is recommended for any confirmed invasive cancer, suspicious lesions that won’t heal, or complex precancerous changes. The common thread is that when cancer is likely or confirmed, a gynecologic oncologist brings the specialized surgical and treatment planning skills that improve outcomes.